Loading...
Please wait, while we are loading the content...
Similar Documents
Method for Diagnosing Traumatic Brain Injury
| Content Provider | The Lens |
|---|---|
| Abstract | It is an object of the present invention to provide a method that can diagnose traumatic brain injury irrespective of its degree, even when it is particularly mild. Disclosed is a method for diagnosing traumatic brain injury, including the steps of: (1) bringing Glial Fibrillary Acidic Protein (GFAP) in a sample collected from a subject into contact with an anti-GFAP capture antibody to form a complex containing the GFAP and the anti-GFAP capture antibody, (2) obtaining a measured value of the GFAP by detecting the GFAP in the complex, and (3) determining whether the subject has traumatic brain injury based on the measured value, wherein the epitope of the anti-GFAP capture antibody is within the 60th to 383rd amino acid sequences in SEQ ID NO: 1. |
| Related Links | https://www.lens.org/images/patent/022-612-498-030-675/pdf/US_2019_A1_20190302127_022-612-498-030-675.pdf |
| Language | English |
| Publisher Date | 2019-10-03 |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Patent |
| Jurisdiction | United States of America |
| Date Applied | 2018-03-30 |
| Applicant | Sysmex Corp |
| Application No. | 201815941698 |
| Claim | A method for diagnosing traumatic brain injury, comprising the steps of: (1) bringing Glial Fibrillary Acidic Protein (GFAP) in a sample collected from a subject into contact with an anti-GFAP capture antibody to form a complex containing the GFAP and the anti-GFAP capture antibody, (2) obtaining a measured value of the GFAP by detecting the GFAP in the complex, and (3) determining whether the subject has traumatic brain injury based on the measured value, wherein the epitope of the anti-GFAP capture antibody is within the 60th to 383rd amino acid sequences in SEQ ID NO: 1. The method according to claim 1 , wherein the traumatic brain injury is mild traumatic brain injury. The method according to claim 1 , wherein the epitope of the anti-GFAP capture antibody is within the 79th to 266th amino acid sequences in SEQ ID NO: 1. The method according to claim 1 , wherein the epitope of the anti-GFAP capture antibody is within the 116th to 214th amino acid sequences in SEQ ID NO: 1. The method according to claim 1 , wherein the epitope of the anti-GFAP capture antibody is within the 192nd to 201st amino acid sequences in SEQ ID NO: 1. The method according to claim 1 , wherein, in the forming step, the GFAP is brought into contact with the anti-GFAP capture antibody and the anti-GFAP detection antibody to form a complex containing the GFAP, the anti-GFAP capture antibody and the anti-GFAP detection antibody. The method according to claim 6 , wherein the epitope of the anti-GFAP detection antibody is within the 79th to 266th amino acid sequences in SEQ ID NO: 1. The method according to claim 6 , wherein the epitope of the anti-GFAP detection antibody is within the 92nd to 105th amino acid sequences in SEQ ID NO: 1. The method according to claim 6 , wherein the epitope of the anti-GFAP detection antibody is within the 257th to 377th amino acid sequences in SEQ ID NO: 1. The method according to claim 6 , wherein the epitope of the anti-GFAP detection antibody is within the 338th to 352nd amino acid sequences in SEQ ID NO: 1. A method for diagnosing traumatic brain injury comprising the steps of: (1) bringing Glial Fibrillary Acidic Protein (GFAP) in a sample collected from a subject into contact with an anti-GFAP capture antibody and an anti-GFAP detection antibody to form a complex containing the GFAP, the anti-GFAP capture antibody and the anti-GFAP detection antibody, (2) obtaining a measured value of the GFAP by detecting the GFAP in the complex, and (3) determining whether the subject has traumatic brain injury based on the measured value, wherein the epitope of the anti-GFAP capture antibody is within the 192nd to 201st amino acid sequences in SEQ ID NO: 1 and the epitope of the anti-GFAP detection antibody is within the 92nd to 105th amino acid sequences in SEQ ID NO: 1. The method according to claim 11 , wherein the traumatic brain injury is mild traumatic brain injury. The method according to claim 1 , wherein, when the measured value is higher than a predetermined standard value, the subject is determined to have traumatic brain injury. The method according to claim 1 , wherein the complex is formed on a solid phase. The method according to claim 14 , wherein the B/F separation is performed after formation of the complex. The method according to claim 14 , wherein the solid phase is a magnetic particle. The method according to claim 1 , wherein the antibody includes an antibody fragment. The method according to claim 1 , wherein the sample is a blood sample. The method according to claim 1 , wherein the complex is formed at 30° C. or more. A method for detecting traumatic brain injury comprising the steps of: (1) bringing Glial Fibrillary Acidic Protein (GFAP) in a sample collected from a subject into contact with an anti-GFAP capture antibody to form a complex containing the GFAP and the anti-GFAP capture antibody, (2) obtaining a measured value of the GFAP by detecting the GFAP in the complex, and (3) determining whether the subject has traumatic brain injury based on the measured value, wherein the epitope of the anti-GFAP capture antibody is within the 60th to 383rd amino acid sequences in SEQ ID NO: 1. |
| CPC Classification | Investigating Or Analysing Materials By Determining Their Chemical Or Physical Properties PEPTIDES MICROORGANISMS OR ENZYMES;COMPOSITIONS THEREOF;PROPAGATING; PRESERVING; OR MAINTAINING MICROORGANISMS;MUTATION OR GENETIC ENGINEERING;CULTURE MEDIA |
| Extended Family | 022-612-498-030-675 |
| Patent ID | 20190302127 |
| Inventor/Author | Lukaszewska Teresa |
| IPC | G01N33/68 C12N5/079 |
| Status | Discontinued |
| Owner | Sysmex Corporation |
| Simple Family | 022-612-498-030-675 |
| CPC (with Group) | G01N33/6896 C07K16/18 G01N33/54326 C12N5/0622 G01N33/6857 G01N2800/28 G01N2800/52 |
| Issuing Authority | United States Patent and Trademark Office (USPTO) |
| Kind | Patent Application Publication |
